Gossamer Bio, Inc. (GOSS)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ: GOSS). Investors who purchased Gossamer securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Gossamer has violated federal securities laws.
Gossamer Investigation Details
On February 23, 2026, Gossamer announced that its Phase 3 PROSERA trial evaluating seralutinib in pulmonary arterial hypertension failed to meet its primary endpoint. Following this news, Gossamer’s stock price fell $1.71 per share, or 80.14%, to close at $0.423 on February 23, 2026.
What’s Next for Gossamer Investors?
If you are aware of any facts relating to this investigation or purchased Gossamer securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Gossamer Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC For Gossamer Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.